Access Pharmaceuticals (OTCQB:ACCP) has licensed the China marketing rights for its oral mucositis product, MuGard, to RHEI Pharma, a US-based company that specializes in bringing proprietary medications to China. RHEI says it has 110 national sales reps with access to large volume hospitals in China. But first, RHEI must put the product through the SFDA approval process.
Once approved, RHEI will manufacture the product in China and seek to market it throughout Southeast Asia. Terms between RHEI and Access were not disclosed.
Access has received approval for MuGard in the US as a medical device, though the company has not attempted to market the product because Access is in a severe cash crunch. In August of 2007, Access licensed European rights for MuGard to SpePharm Holding, BV for $1 million. Access has said that it is seeking a marketing partner for US distribution.
MuGard is a ready-to-use mucoadhesive oral wound rinse. The mucoadhesive formulation forms a protective coating over the oral mucosa when washed around the mouth. In clinical tests conducted among patients receiving radiation treatment for head and neck cancer, MuGard increased the number of patients protected from mucositis to 47%, which is much higher than the historical norm of 7%.
Clinical practice guidelines for the prevention and treatment of mucositis now recommend a preventive oral care regimen along with a therapeutic oral care regimen when mucositis develops.
Both Access and RHEI are building portfolios of cancer care products.